Tonghua Dongbao 2021 results: Net profit attributable to parent up 40.69% YoY

On the evening of April 18, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its annual report for 2021. In 2021, t...

Tonghua Dongbao: Phase I clinical trial application for BC Combo approved in Germany

Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") was approved by the Federal Institute for Drugs and Medical Devices (BfArM) in Germany for the phase I clinical trial of B...

Tonghua Dongbao sells some of its shares in Amoytop again to accelerate innovation and R&D

On March 17, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") announced its plan to transfer 20.5 million shares (or 5.04% of total share capital) in Xiamen Amoytop ...

Tonghua Dongbao: Clinical trial application for BC Combo approved

Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received the notification of approval (No. 2022LP00393) from the National Medical Products Administration (NMPA) on the clinical trial application for BC Combo (THDB0207 injection), a soluble insulin glargine and insulin lispro injection. The acceptance number is CXSL210151.

Tonghua Dongbao: No more than RMB 360 million of shares planned for repurchase and cancellation

On the evening of March 9, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") announced its plan to buy back no fewer than 12 million and no more than 240 million shares with its own funds through centralized bidding transactions, accounting for 0.60% to 1.19% of the Company's total share capital. The repurchase is expected to last 6 months from the date when the repurchase plan is approved at the shareholders meeting. As planned, the unit price of the repurchased shares will not exceed RMB 15, and the total repurchase amount will be no more than RMB 360 million.

Tonghua Dongbao: First subject enrolled in phase I clinical trial of the world's first triple-target inhibitor (SGLT1/ SGLT2/ DPP4)

Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") has initiated the phase I clinical trial of its triple-target inhibitor (THDBH101 Tablets/WXSHC071 Tablets) in China, after receiving the notice of approval from the National Medical Products Administration (NMPA). Recently, the first subject has been successfully enrolled.